Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:39:23 EDT Wed 06 Aug 2025
Enter Symbol
or Name
USA
CA



Q:CORT - CORCEPT THERAPEUTICS INC - https://www.corcept.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CORT - Q1.469.65·69.936.869.83-0.62-0.994.96,5331,76269.56  70.6045  69.31117.33  33.3410:23:00Jul 3115 min RT 2¢

Recent Trades - Last 10 of 1762
Time ETExPriceChangeVolume
10:23:06Q69.62-0.835
10:23:06Q69.62-0.831
10:23:06Q69.60-0.851
10:23:06Q69.60-0.859
10:23:06Q69.63-0.823
10:23:06Q69.63-0.82100
10:23:06Q69.65-0.8038
10:23:06Q69.65-0.8038
10:23:06Q69.65-0.8024
10:23:06Q69.63-0.82100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-31 16:05U:CORTNews ReleaseCorcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
2025-07-24 16:05U:CORTNews ReleaseCorcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
2025-07-14 08:00U:CORTNews ReleaseCorcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
2025-06-23 16:30U:CORTNews ReleaseCorcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association's 85th Scientific Sessions with Simultaneous Publication in Diabetes Care
2025-06-05 06:00U:CORTNews ReleaseCorcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
2025-06-02 11:15U:CORTNews ReleaseCorcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
2025-05-05 16:05U:CORTNews ReleaseCORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
2025-04-28 16:05U:CORTNews ReleaseCORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL
2025-04-23 11:30U:CORTNews ReleaseCORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025
2025-04-21 08:00U:CORTNews ReleaseDiabetes Care Publishes Results From Prevalence Phase Of Corcept's CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes
2025-04-07 08:00U:CORTNews ReleaseCorcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer
2025-03-31 08:00U:CORTNews ReleasePrimary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
2025-03-10 08:00U:CORTNews ReleaseCorcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension
2025-03-03 16:05U:CORTNews ReleaseFDA Files Corcept's New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism
2025-02-26 16:05U:CORTNews ReleaseCorcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update
2025-02-12 16:05U:CORTNews ReleaseCorcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call
2024-12-30 17:15U:CORTNews ReleaseCorcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism
2024-12-16 08:00U:CORTNews ReleaseCorcept's Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism
2024-12-12 16:05U:CORTNews ReleaseCorcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control Diabetes
2024-12-11 16:05U:CORTNews ReleaseCorcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)